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The aim of this study is to evaluate different options for introducing liquid-based cytology (LBC) and human papillomavirus (HPV)
testing into the UK cervical cancer screening programme. These include options that incorporate HPV testing either as a triage for
mild and borderline smear abnormalities or as a primary screening test. Outcomes include the predicted impact on resource use,
total cost, life years and cost–effectiveness. Extensive sensitivity analysis has been carried out to explore the importance of the
uncertainty associated with disease natural history and the impact of screening. Under baseline assumptions, the cost–effectiveness of
different options for introducing LBC appears favourable, and these results are consistent under a range of assumptions for its impact
on the diagnostic effectiveness of cytology. However, if we assume a higher marginal cost of LBC in comparison to conventional
methods, primary smear testing options are predicted to be more cost-effective without LBC. Combined LBC primary smear and
HPV testing with a 5-year interval is similar in both cost and effectiveness to the other 3-yearly options of primary smear testing or
primary HPV testing alone. However, both primary HPV testing and combined options would give rise to a far greater risk of
inappropriate colposcopy throughout a woman’s lifetime.
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Liquid-based technology has been developed for the purpose of
improving the preparation of cervical smear samples, and a range
of different methods are available which include AutoCytePrep,
Easy Prep, Cytoscreen and Thinprep. Each involves the prepara-
tion of potentially better and more representative smear samples
for cytological examination than with conventional means, with a
consequent reduction in the number of inadequate specimens and
an increase in sensitivity. In practice, however, the actual impact
on the performance of cytology is still a matter of some debate
since different studies have reported very different findings.
Currently, in the UK, around 10% of all smear samples are
classified as inadequate, and the recent Pilot Site evaluation of
liquid-based cytology (LBC) in the UK found that the new
technology reduced this figure to 2% (Moss et al, 2002). However,
there are other studies that have reported very little impact
(Dupree et al, 1998; Diaz-Rosario and Kabawat, 1999). Similarly,
with smear test sensitivity, some studies have demonstrated
improvements (Nanda et al, 2000), while others have found little
(Moss et al, 2002; Coste et al, 2003).
As human papillomavirus (HPV) testing technology has
developed, the inclusion of HPV testing within cervical screening
programmes has been suggested, either as a triage for women
presenting with borderline and mildly abnormal smears (Cox et al,
1995) or as a primary screen (Cuzick et al, 1999b; Cuzick et al,
2003). It has also been suggested that, with HPV testing, routine
screening intervals could be lengthened without compromising
effectiveness. Under conventional cytology, a separate smear
sample needs to be taken for the HPV test, whereas with liquid-
based preparations, the same smear sample could be used for both
cytology and the HPV test (Ferenczy and Franco, 1997). This may
make the introduction of HPV testing more viable, with important
implications for cost and convenience. It may also mean that
screening options that combine smear and HPV testing in primary
screening become worthwhile (Meijer et al, 1997).
The purpose of this study is to evaluate different options for
introducing LBC within the UK, in terms of the impact on resource
use, cost, effectiveness and overall cost–effectiveness. The merits
of liquid-based approaches are also compared with other changes
that could be made to the screening programme keeping
conventional techniques, including the introduction of HPV
testing. This is the only study that compares such a range of
options simultaneously. The study does not investigate one
specific liquid-based method but a range of approaches defined
by different characteristics of cost and impact. We have used a
mathematical modelling approach based upon methods developed
by the authors in previous studies (Jenkins et al, 1996; Sherlaw-
Johnson et al, 1999). Mathematical modelling has value in this
context since it provides a method for assessing a wide range of
screening options relatively quickly.
METHODS
Mathematical model
The main elements of the model are the clinical course of cervical
disease and resulting mortality, age-related mortality from other
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lcauses, the accuracy of screening tests and the screening policy.
The model is stochastic in that we use methods from probability
theory to represent the considerable variability in possible outcomes.
The clinical course of the disease and the development of
invasive cancer are represented by a sequence of transitions
through cervical precancer and stages of preclinical and clinically
invasive cancer (Figure 1). Precancers are assumed to be preceded
by high-risk HPV infection (most commonly, types 16, 18, 31 and
33), and are divided into three separate states corresponding to the
three grades of cervical intraepithelial neoplasia (CIN 1–3). The
cancer states correspond to the International Federation of
Gynecology and Obstetrics (FIGO) classification stages I–IV.
Although not indicated in Figure 1, account is also taken of deaths
from other causes, which, after correcting for age and sex, are
assumed to be independent of the stage of cervical disease. This
disease progression model is stochastic in that the transitions
between states are assumed to be a chance process with a specified
probability assigned to each transition. Starting with a woman
aged 15 years who is free from disease, the model predicts the
probability of being in each disease category at all subsequent ages.
If the woman is screened then the chances of detecting any
precancerous lesion, or preclinical cancer will depend on the
accuracy of the screening test. Successful detection and treatment
of precancerous lesions are modelled by assuming that women
revert to being disease free, with a prespecified proportion of HPV
infections regressing simultaneously. Screening occurs at different
ages depending upon the programme and the policy for the follow-
up of abnormal results. Under the baseline assumptions,
successive HPV tests on the same women are assumed to be
independent, but the possibility that HPV remains undetectable in
certain women over a series of tests is also assessed.
Parameter values for the model have been derived from existing
data sources. However, there is much uncertainty relating to these
values with several sources reporting very different results. Owing
to this uncertainty, we have undertaken extensive sensitivity
analysis to investigate how it affects outcomes.
Natural history assumptions
Structurally, the disease progression model is a continuous time
Markov Process governed by instantaneous hazard rates between
each state (Ross, 1993). The implications of the chosen rate
parameters in terms of more easily interpreted annual progression
rates are shown in Table 1, together with references to the studies
from which they have been derived. (Detailed assumptions are
available from the authors by request.) For many disease
progression parameters, direct estimates are not available from
the literature. Values have thus been inferred from observed data
such as the prevalence of HPV infection, the overall incidence of
invasive cancer and the prevalence of precancers detected among a
screened population. This method has not generated a unique set
of parameters, but rather a number of plausible sets that have all
been used by the model to explore the consequences of different
disease progression scenarios. These scenarios are defined by
different rates of prevalence and persistence of HPV infection, and
the incidence of cervical cancer if the current population were not
screened. The range of values encompassed by these scenarios is
also shown in Table 1. The baseline scenario was validated against
the age-related incidence of invasive cancer in the UK (Office for
National Statistics, 2003).
Diagnosis
Other parameters used in the model that relate to diagnostic
accuracy and the impact of LBC are shown in Table 2. There is also
much uncertainty relating to these values: several studies and
different techniques report very different results. Owing to this
uncertainty, we have investigated the consequences of using a
range of values for the same parameter (also shown in Table 2).
Costs
Costing was undertaken from the perspective of the health care
provider. All costs are represented as 2001 values and are
summarised in Table 3. The cost of conventional smear taking is
derived from primary resource utilisation data. In total, 66 GP
practices in the UK completed a questionnaire regarding the time
spent on smear taking, administration and the personnel involved.
On average, 85% of smears were taken by a practice nurse, 14% by
the GP and 1% by hospital or family planning personnel. The
average time spent on a smear (including preparation) was
between 14 and 18min. Staff time was valued using standard
sources (Netten et al, 2001; CIPFA, 2002). As a base case assump-
tion, the time involved in smear taking using LBC was assumed to
be 4min less than with conventional methods. This assumption
was varied in sensitivity analysis. The smear taker was assumed to
follow the same distribution as for conventional methods. Primary
care administration was found to take on average 3.7h per week
and each practice in the survey performed approximately 12.5
smear tests per week. We had no grounds to assume that
administration costs would differ between conventional and LBC
methods. NHS administration, including GP target payments, are
excluded from these estimates. Laboratory costs for conventional
cytology are based on an audit of the City Hospital cytology
laboratory in Nottingham, and include staff costs, equipment
(including maintenance), transport and consumables. Under LBC,
staffing within the laboratory was assumed to be equal to those of
conventional cytology. Equipment, consumables and maintenance
costs for LBC methods are taken from reported data (Payne et al,
2000). Human papillomavirus test costs include staff time,
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Figure 1 Model representation of disease natural history.
Liquid-based cytology and human papillomavirus testing
C Sherlaw-Johnson and Z Philips
85
British Journal of Cancer (2004) 91(1), 84–91 & 2004 Cancer Research UK
C
l
i
n
i
c
a
lequipment (inc. maintenance) and consumables. Human papillo-
mavirus test transportation costs are not included in this estimate.
Cervical intraepithelial neoplasia and invasive cancer treatment
costs are taken from detailed cost of illness studies (Wolstenholme,
2002; Wolstenholme and Whynes, 1998). Further details of
resource use and costing methods are available on request.
Screening
The screening options evaluated in this study include:
(i) screening all women from age 21 to 64 years. Mildly abnormal
and borderline results during routine screening are followed
up according to UK recommendations for repeat cytology;
(ii) routine screening as in (i) with HPV testing as a triage for
mild and borderline smear results during routine screening. If
the HPV test is positive for high-risk types, women are referred
for colposcopy, otherwise they have repeat cytology as in (i);
(iii) option (i) until the age of 30 years after which routine smear
testing is replaced by primary HPV testing with cytology as a
triage for women found to be positive for high-risk HPV
types. If the cytological result is abnormal, women are
referred for colposcopy, otherwise they have a follow-up HPV
test in 6 months. If this repeat HPV test is negative, women
revert to routine screening;
(iv) option (i) until the age of 30 years, after which primary smear
testing is combined with HPV testing. Women with moderate
or severe smear abnormalities are referred for colposcopy.
Table 1 Assumptions concerning the natural history of HPV and cervical precancers (alternative assumptions in parentheses)
Parameter Value Reference
Percentage of women contracting high-risk HPV
infections over a given year
30% declining to 0% with age (20% declining to 0%,
40% declining to 0%)
Prevalence data: Melkert et al (1993); Cuzick et al
(1999a)
Mean persistence of HPV infections 1 year increasing to 17 years with age (1.5
increasing to 28)
Incidence and regression: Hildesheim et al (1994);
Moscicki et al (1993); Ho et al (1998)
Percentage of women contracting CIN over a given
year in the absence of high-risk HPV
0% for all ages (0.8% decreasing to 0% with age)
Percentage of high-risk HPV infections progressing
to CIN over a year
19% increasing to 24% with age Progression and regression:H oet al (1998); Koutsky
et al (1992)
Percentage of CIN 1 lesions progressing over a year 13% increasing to 17% with age (19% increasing to
24% with age)
Cancer incidence data: Office for National Statistics
(2003)
Percentage of CIN 2 lesions progressing over a year 17%
Percentage of CIN 3 lesions progressing over a year 0.7% Screening and colposcopy data: Department of
Health (2001)
Annual regression of CIN 1 lesions 70% declining to 20% with age
Annual regression of CIN 2/3 lesions 7% declining to 2% with age
Mean duration of preclinical invasive cancer stages Stage 1: 5 months; stage 2: 1.5 months; stage 3: 1
months; stage 4: 20 days
Stage distribution of new clinical cancers Stage 1: 40%; stage 2: 31%; stage 3: 21%; stage 4:
8%
Proportion of stage 1 cancers cured 95% decreasing to 70% with age (89% decreasing
to 65%)
Meanwell et al (1988); Kosary (1994); Office for
National Statistics (1999)
Proportion of stage 2 cancers cured 65% decreasing to 45% (61% decreasing to 42%)
Proportion of stage 3 cancers cured 45% decreasing to 30% (35% decreasing to 26%)
Proportion of stage 4 cancers cured 20% decreasing to 10% (14% decreasing to 7%)
Age-related mortality from other causes England and Wales, female life tables Government Actuary’s Department, 1996
CIN¼cervical intraepithelial neoplasia; HPV¼human papillomavirus.
Table 2 Assumptions concerning the performance of screening tests (alternative assumptions in parentheses)
Parameter Value Reference
Probability of a borderline or mild smear result given
the underlying histology
Normal 2.8% (2.0%)
CIN 1 53%
CIN 2 23% (30%)
CIN 3 24% (20%) Baseline: Cuzick et al (1995)
Invasive cancer 40% Invasive cancer: inferred from Department of Health (2001)
Probability of a moderate or severe smear result given
the underlying histology
Normal 0.6% (0%) Range: Jenkins et al (1998)
CIN 1 14%
CIN 2 18% (40%)
CIN 3 41% (60%)
Invasive cancer 60%
Sensitivity of HPV test at detecting high-grade CIN 88% (65%, 95%) Baseline: Schiffman et al (2000). Range: Jenkins et al (1998)
Proportion of inadequate smear results 10% (5%) Department of Health (2001)
Impact of liquid-based cytology on smear test sensitivity No increase (40% increase in detected
precancers)
Baseline: Moss et al (2002) Alternative: Payne et al (2000)
Proportion of inadequate smear test results with liquid-
based cytology
5% (2%, 10%) Baseline and upper alternative: Payne et al (2000); McCrory et al
(1999)
Lower alternative: Moss et al (2002)
Liquid-based cytology and human papillomavirus testing
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lWomen with mild or borderline smear results, or a negative
smear and a positive HPV test undergo repeat combined testing
at 6-month intervals. Women revert to routine screening after a
combination of a clear smear test and negative HPV result.
Option (i) approximates to current recommended screening
policy in the UK. The other options are based upon suggested
strategies for including HPV testing as a triage (Beral and Day,
1992; Cox et al, 1995), as a primary screen with cytology as a triage
(Cuzick et al, 2003), or combined with cytology as a primary
screen (Meijer et al, 1997; Cuzick et al, 1999b).
Each screening option was evaluated with 3- and 5-year routine
intervals and both with and without LBC. We have assumed that
85% of eligible women throughout the population are screened,
which is similar to current coverage rates in the UK (Department
of Health, 2001), and that this is the same for all ages at which
women are screened.
Outcomes
Outcomes are presented as average and incremental costs and life
years gained over the lifetime of women aged 15 years, and who are
exposed to each screening option throughout (although not
necessarily attending). In line with current UK recommendations,
future costs and life years were discounted at 3.5% per annum,
along with the consequences of no discounting and of discounting
costs and life years at 6% per annum (National Institute for
Clinical Excellence, 2003).
Incremental cost–effectiveness ratios are defined as the ratio of
the difference between cost and outcome of moving from one option
to the next in order of increasing cost. In calculating incremental
cost–effectiveness ratios, all dominated and extendedly dominated
options are excluded. An option is ‘dominated’ if there is another
option which is both cheaper and more effective. An option is
‘extended dominated’ if it is not dominated by a single other option,
but there is a combination of two options that is both cheaper and
more effective (Drummond et al, 1997). Options that are neither
dominated nor extended dominated define the ‘efficiency frontier’.
RESULTS
Costs and effectiveness
With the baseline assumptions, average lifetime costs and life
expectancy from age 15 years are shown in Table 4, together with
the corresponding incremental cost–effectiveness ratios. All options
that do not involve LBC are dominated. Incremental costs and life
years saved for each option are also illustrated in Figure 2, together
with the efficiency frontier. Apart from the two combined options,
the 5- and 3-yearly screening options form two distinct groups, with
the 5-year combined option having similar results to the other 3-
year strategies. All the options that include LBC are either on, or
very close to the efficiency frontier, except, perhaps for the 3-year
repeat cytology strategy. Figure 2 also indicates that the main impact
of LBC is a cost reduction as opposed to improved effectiveness.
Other outcomes are shown in Table 4, including the percentage
of deaths due to cervical cancer that are averted by screening and
the lifetime rate of detection of high-grade CIN. The final column
shows the lifetime risk of an inappropriate referral for colposcopy,
with a referral being ‘inappropriate’ if there are no precancerous or
cancerous lesions present. The risk of inappropriate referral is
highest under the primary HPV and combined options where it
can be over 50%, while under primary smear testing, the risk is no
higher than 16%.
Sensitivity analysis
The results of one-way sensitivity on the impact of LBC and
discounting are shown in Table 5. The options are again listed in
order of increasing cost, except where indicated. Even if LBC has
no impact on the number of inadequate smears, all the conven-
tional options are still dominated. Although not indicated by this
table, the options that involve primary smear testing and LBC with
HPV triage consistently lie on, or close to the efficiency frontier. If
we assume a high marginal cost of LBC over conventional smears,
options that involve conventional methods are predicted to be
cheaper for primary smear testing, but not for primary HPV testing.
Figure 3 shows the results of multiway sensitivity analysis on the
impact of four options for using LBC in comparison to 3-year
screening with repeat cytological follow-up and no LBC. Since this
latter strategy is an approximation to current recommended
practice in the UK, the graph shows the likely impact of changing
policy. This multiway analysis includes all possible combinations
of alternative assumptions as specified in Tables 1–3 and so
represents the full range of uncertainty under the baseline discount
rates. The two primary smear testing options are consistently
predicted to either match or increase effectiveness. The less-precise
forecasts for the combined, and, in particular, the primary HPV
testing options are consequences of the uncertainty regarding the
Table 3 Unit cost assumptions for screening strategies and follow-up
Item Cost (d) (ranges in parentheses) Source
Conventional screening Takers and administration costs: Netten et al (2001); CIPFA (2002)
Smear test 20.76 (19.69–21.84)
HPV test 22.29 (20.29–25.29) Laboratory and HPV costs: Laboratory Accounts
Primary smear testing with LBC LBC costs: Payne et al, 2000.
Smear test 20.00 (18.93–23.60)
Marginal cost of HPV test 11.79 (9.79–14.79)
Primary HPV testing with LBC
HPV test 20.21 (18.21–23.21)
Marginal cost of smear test 11.58 (10.51–15.18)
Colposcopy 71.19 (56.95–85.43)
Punch biopsy 59.02 (47.22–70.82) Wolstenholme 2002,
CIN I 311 (249–373)
CIN II 343 (274–412)
CIN III 369 (295–443)
Stage 1 invasive cancer 9772 (7818–11726)
Stage 2 invasive cancer 16097 (12878–19316) Wolstenholme and Whynes 1998
Stage 3 invasive cancer 15991 (12793–19189)
Stage 4 invasive cancer 17020 (13616–20424)
Liquid-based cytology and human papillomavirus testing
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laccuracy and prevalence of the HPV test. Decreased effectiveness
will occur with combinations of a test that is less accurate than the
baseline assumption, an assumption that some HPV remains
consistently difficult to detect and an assumed higher prevalence
of infection in older women.
DISCUSSION
The purpose of this study has been to evaluate and compare
options for introducing LBC and/or HPV testing into cervical
cancer screening programmes. All the screening options have been
chosen to reflect those that have been previously proposed or
evaluated. However, this is the only study that has evaluated all
screening options in combination.
Under baseline assumptions, the cost–effectiveness of different
options for introducing LBC appears favourable, and these
results are consistent under a range of assumptions for its
impact on the diagnostic effectiveness of cytology. However, the
marginal cost of LBC does affect outcomes. If we assume a higher
marginal cost of LBC in comparison to conventional methods,
primary smear testing options are predicted to be more cost-
effective without LBC. The cost–effectiveness of primary HPV
testing with LBC appears less sensitive to changes in the LBC
marginal cost, but this is because in our one-way sensitivity
analysis, variability in cost is only associated with the cytology
laboratory costs and not HPV costs. Combined primary smear and
HPV testing with a 5-year interval is similar in both cost and
effectiveness to the other 3-yearly options. However, both the
primary HPV testing and combined options would give rise to a far
Table 4 Outcomes under baseline assumptions. Incremental cost–effectiveness ratios represent the cost for every year of life gained by adopting the
more expensive option in favour of the next cheapest, nondominated option
Options in order of increasing
cost
Average lifetime
cost of
screening and
treatment
(discounted at
3.5% p.a.)
Average life
expectancy
from age 15
years
(discounted at
3.5% p.a.)
Incremental
cost–
effectiveness
ratios
Total deaths
averted
CIN 2/3
detected per
lifetime
Inappropriate
referrals for
colposcopy per
lifetime
No screening d86.14 25.292 ————
Repeat cytology with LBC, 5 years d159.79 25.316 ED 64.89% 0.152 0.084
HPV triage with LBC, 5 years d162.54 25.317 d3,067 67.63% 0.157 0.099
Repeat cytology without LBC, 5
years
d166.06 25.316 D 64.89% 0.152 0.083
Primary HPV with LBC, 5 years d169.50 25.319 d3,720 71.29% 0.156 0.390
HPV triage without LBC, 5 years d170.38 25.317 D 66.72% 0.157 0.099
Primary HPV without LBC, 5 years d187.72 25.318 D 68.55% 0.150 0.367
Repeat cytology with LBC, 3 years d214.59 25.320 ED 73.12% 0.170 0.132
HPV triage with LBC, 3 years d219.23 25.321 ED 74.95% 0.175 0.158
Combined cytology and HPV with
LBC, 5 years
d219.50 25.321 d22,628 77.69% 0.166 0.515
Repeat cytology without LBC, 3
years
d224.13 25.320 D 72.20% 0.170 0.131
Primary HPV with LBC, 3 years d227.87 25.321 ED 74.03% 0.153 0.613
HPV triage without LBC, 3 years d231.17 25.321 D 74.03% 0.175 0.157
Primary HPV without LBC, 3 years d256.01 25.320 D 70.38% 0.147 0.574
Combined cytology and HPV with
LBC, 3 years
d309.58 25.323 d37,846 80.43% 0.160 0.810
D¼dominated; ED¼extended dominated; LBC¼liquid-based cytology; HPV¼human papillomavirus.
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Figure 2 Incremental costs and life years gained of different options in comparison to no screening. Costs and life years are discounted at 3.5% per
annum.
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lgreater risk of inappropriate colposcopy throughout a woman’s
lifetime.
Adding LBC to the current programme is predicted to match or
improve effectiveness under the full range of assumptions used for
sensitivity analysis, and, likewise, if it was further modified by
adding HPV testing as a triage for mild or borderline smear
abnormalities. Changing to the combined smear and HPV testing
option and raising the screening interval to 5 years, could improve
effectiveness, similarly if the programme is changed to primary
HPV testing. However, under these options, the predicted impact
is less robust to the assumptions we have made: their effectiveness
being very sensitive to the relative diagnostic accuracy of the HPV
test in relation to cytology, HPV prevalence and whether there is
any consistent difficulty in detecting HPV infections in some
women.
Since a modelling approach has been used, there has been scope
for analysing a wide range of options. Several different sce-
narios have been analysed to allow for the uncertainty regarding
the model parameters. This uncertainty not only reflects the range
of estimates reported in the scientific literature, but also the
imprecise knowledge regarding the natural history and age-related
prevalence of HPV infections and cervical precancers both now
and in the future. Evaluating different scenarios has enabled us to
investigate how robust predicted outcomes are to changes in
model assumptions, to identify areas of uncertainty that have a
large influence on outcome, and identify circumstances under
which particular options are less favourable.
The costs used in the model are based on best estimates
currently available, although no account has been taken of
the training and transfer costs associated with moving from
the current screening programme to one including LBC and/or
HPV testing and neither have transportation costs for HPV
samples been included. It is recognised that the prospective
resource utilisation data come from a relatively small number of
practices in the UK and the cost data for LBC are based largely on
assumption.
Table 5 Incremental costs per life year gained under different assumptions relating to the performance and cost of LBC
Options in order of increasing
cost except where specified Baseline
No impact on
inadequates
Inadequates
reduced to 2% of
all smears
Marginal cost of
LBC¼d3.60
c No discounting
Discounting
costs and life
years at 6% p.a
No screening ——————
Repeat cytology, LBC, 5-yearly ED ED ED D ED ED
HPV Triage, LBC, 5-yearly d3067 ED d2990 D d683 ED
Repeat cytology, no LBC, 5-yearly D D D ED D D
Primary HPV, LBC, 5-yearly d3720 d3167 d4027 d3368 d2011 d6588
HPV Triage, no LBC, 5-yearly D D D ED D
a D
Primary HPV, no LBC, 5-yearly DDDDDD
Repeat cytology, LBC, 3-yearly ED ED ED D ED D
HPV Triage, LBC, 3-yearly ED ED ED D ED ED
Combined, LBC, 5-yearly d22628 d18486 D ED d9309 ED
b
Repeat cytology, no LBC, 3-yearly D D
b DE DD
a D
Primary HPV, LBC, 3-yearly ED D d24149 d26242 D d34093
a
HPV Triage, no LBC, 3-yearly D D D ED D
a D
Primary HPV, no LBC, 3-yearly DDDDDD
Combined, LBC, 3-yearly d34,686 d38910 d46569 d44362 d21115 d68198
Monetary values represent the cost for every year of life saved by adopting the more expensive option in favour of the next cheapest, nondominated option. D¼dominated;
ED¼extended dominated; LBC¼liquid-based cytology; HPV¼human papillomavirus.
aThis option is cheaper than the one above.
bThis option is cheaper than the two above.
cUnder this assumption, the order of the LBC and non-LBC options for each of the repeat cytology and HPV triage options are reversed.
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Primary HPV testing with LBC, 3-year interval
Figure 3 Incremental costs and life years gained of different options in comparison to the baseline option of 3-year screening with repeat cytology
following mild or borderline smear results and no LBC. Costs and life years are discounted at 3.5% per annum. The areas represent the range of outcomes
from all possible combinations of alternative assumptions used in the sensitivity analysis, except discounting.
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lPrevious studies have analysed the impact of LBC on cervical
screening programmes (McCrory et al, 1999; Payne et al, 2000;
Kim et al, 2002; Moss et al, 2002). All are based wholly, or partly on
mathematical modelling, but none have investigated the whole
range of options in this study together. All studies conclude that
introducing LBC within a primary smear testing programme could
be cost-effective with (Kim et al 2002), or without (McCrory et al,
1999; Payne et al, 2000; Moss et al, 2002) HPV testing as a triage.
They all predict improvements in effectiveness, but the impact on
cost depends on the assumed marginal cost for the new
technology. Of these, the lowest marginal cost was calculated by
the UK Cervical Screening Pilot Site study, which is the only one to
predict overall cost savings. This study also found that LBC
reduces the number of inadequate smears by about 80% yet has
little impact on test sensitivity. Three studies have investigated
combined smear and HPV testing and HPV testing alone as
primary screening methods, but without LBC (Van Ballegooijen
et al, 1997; Cuzick et al, 1999b; Mandelblatt et al, 2002). The latter
of these only compared 2- and 3-year screening intervals, yet found
a combined test to be feasible if extended to an older age group.
The two former studies, as with this study, found combined
screening options at 3- and 5-year intervals to be more costly yet
more effective than 3-year smear testing, much of the extra cost
being due to screening and surveillance. Also, similar to our own
findings, the relative impact of primary HPV testing was less robust
to different versions of their model and so difficult to determine.
The mathematical model is a tool for making the best use of the
available information, yet the results cannot be treated as
definitive. There are further factors that have not been investigated
which could influence the outcomes. Women are assumed to be
either always compliant or not, and no account has been taken of
how compliance, and hence effectiveness, could be improved by
reducing the number of tests a woman is required to attend, for
example, by extending the screening interval, combining smear
and HPV tests and reducing the number of inadequate smears. The
performance of screening tests has also assumed to be the same for
all ages, although there is evidence that cytological accuracy
declines among older women (Mandelblatt et al, 1991). There is
much controversy over appropriate discount rates, and incre-
mental cost–effectiveness ratios can only be interpreted against
the rates that are chosen. However, alternative views of discount-
ing have little impact on how different options stand in relation to
each other.
The aim of this study was to evaluate screening in the context of
the UK, and care would need to be taken before translating its
results to other settings. International comparisons of cost–
effectiveness are hampered by differences in health systems,
resource and cost structures, chosen comparators and recom-
mended methods for evaluating technologies. Guidelines on
appropriate discount rates differ between countries; in the United
States for example, the current recommendations are 3% for both
costs and life years (Weinstein et al, 1996). Perhaps more
importantly, at 9–10%, the proportion of smears classified as
inadequate is particularly high in the UK in comparison to other
developed countries, and, as a result, any reduction in this
proportion due to the introduction of liquid-based technology may
be of greater benefit than elsewhere.
Since cost and life years saved are not the only outcomes of
importance, other measures could come to the fore in the decision
making process. In terms of the psychological impact on women,
high false positive rates for referral to colposcopy may count
against the acceptability of primary HPV testing and combined
primary smear and HPV testing. This may also be an unnecessary
use of expensive resources. The HART study, however, suggested
that this problem could be overcome in primary HPV testing by
annual monitoring of women who are HPV positive with border-
line or negative cytology (Cuzick et al, 2003). Also, for women
being screened, lower numbers of inadequate smears would be
desirable, and evidence suggests such reductions occur with LBC
without compromising sensitivity (Moss et al, 2002).
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